CN116640833B - A method for automatically batch detecting mRNA capping rate using capillary electrophoresis technology - Google Patents
A method for automatically batch detecting mRNA capping rate using capillary electrophoresis technology Download PDFInfo
- Publication number
- CN116640833B CN116640833B CN202310642481.5A CN202310642481A CN116640833B CN 116640833 B CN116640833 B CN 116640833B CN 202310642481 A CN202310642481 A CN 202310642481A CN 116640833 B CN116640833 B CN 116640833B
- Authority
- CN
- China
- Prior art keywords
- mrna
- capillary electrophoresis
- hybridization probe
- probe
- electrophoresis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 139
- 238000005251 capillar electrophoresis Methods 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000005516 engineering process Methods 0.000 title claims abstract description 11
- 239000000523 sample Substances 0.000 claims abstract description 100
- 238000009396 hybridization Methods 0.000 claims abstract description 30
- 238000004925 denaturation Methods 0.000 claims abstract description 15
- 230000036425 denaturation Effects 0.000 claims abstract description 15
- 238000000746 purification Methods 0.000 claims abstract description 11
- 108020003589 5' Untranslated Regions Proteins 0.000 claims abstract description 9
- 238000010494 dissociation reaction Methods 0.000 claims abstract description 7
- 230000005593 dissociations Effects 0.000 claims abstract description 7
- 238000001962 electrophoresis Methods 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000137 annealing Methods 0.000 claims description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- 102000004157 Hydrolases Human genes 0.000 claims description 8
- 108090000604 Hydrolases Proteins 0.000 claims description 8
- 102100034343 Integrase Human genes 0.000 claims description 7
- 101710203526 Integrase Proteins 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 108010052833 ribonuclease HI Proteins 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 9
- 238000000926 separation method Methods 0.000 abstract description 5
- 238000005266 casting Methods 0.000 abstract description 3
- 238000012795 verification Methods 0.000 abstract description 3
- 238000001228 spectrum Methods 0.000 abstract description 2
- 238000013518 transcription Methods 0.000 description 17
- 230000035897 transcription Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000499 gel Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000001821 nucleic acid purification Methods 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 102000007863 pattern recognition receptors Human genes 0.000 description 3
- 108010089193 pattern recognition receptors Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101001131592 Homo sapiens Periodic tryptophan protein 2 homolog Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102100034421 Periodic tryptophan protein 2 homolog Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 101150005884 ctp1 gene Proteins 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- AGWRKMKSPDCRHI-UHFFFAOYSA-K [[5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical compound COC1C(OP([O-])(=O)OCC2OC(C(O)C2O)N2C=NC3=C2N=C(N)NC3=O)C(COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OCC2OC(C(O)C2O)N2C=[N+](C)C3=C2N=C(N)NC3=O)OC1N1C=NC2=C1N=CN=C2N AGWRKMKSPDCRHI-UHFFFAOYSA-K 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012398 clinical drug development Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 108010032819 exoribonuclease II Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108010027510 vaccinia virus capping enzyme Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a method for automatically detecting mRNA capping rate in batches by utilizing capillary electrophoresis technology, belonging to the technical field of biological detection. Hybridizing a hybridization probe designed according to the 5' UTR region sequence of mRNA to be detected with the mRNA to be detected to obtain a heterozygous sequence, and carrying out enzymolysis, purification and high-temperature denaturation and dissociation on the heterozygous sequence to obtain probe, capped and uncapped mRNA sequences. The capillary electrophoresis equipment is used for analyzing the mRNA capping rate, and the automatic batch quantitative detection of the mRNA capping rate can be realized by setting a reverse electrophoresis program and a specific gel casting and gel storage program. The capillary electrophoresis spectrum obtained by the invention has smooth characteristic peak base line, high signal-to-noise ratio and high separation degree between signal peaks of the capped sample and the uncapped sample although the molecular weights of the capped sample and the uncapped sample are similar. The invention has simple operation, low consumable cost, accurate and repeatable experimental result, and is very suitable for quality verification in mRNA medicine industrialization.
Description
Technical Field
The invention relates to the technical field of biological detection, in particular to a method for automatically detecting mRNA capping rate in batches by utilizing a capillary electrophoresis technology.
Background
MRNA is used as a transient carrier of genetic information and can be synthesized into proteins by cellular machinery. The method has excellent potential in drug development due to the characteristics of safety, strong, quick, flexible and programmable production. Thus, mRNA drugs are very attractive as a novel nucleic acid drug, and related needs are increasing.
The most critical step in mRNA drug preparation is the production of structurally intact and biologically active mRNA stocks. The in vitro synthesized mRNA needs to have a complete structure to perform normal biological functions. The smallest mRNA structure typically comprises a 5 'cap, a 5'/3 'untranslated region (Untranslated region, UTR), an Open reading frame encoding a protein (Open READING FRAME, ORF) and a 3' poly a tail. The structure of mRNA transcribed by eukaryotic RNA polymerase II, which is co-transcribed and modified at its 5' end, is called a cap. The cap structure is critical for mRNA: ① mRNA caps promote efficient translation of mRNA by recruiting translation initiation factors; ② The cap structure can protect mRNA from rapid degradation of exonuclease, so that the relative stability of mRNA is effectively maintained; ③ For drug development, mRNA lacking the cap structure will be recognized in the body as "abnormal" by the innate immune sensor pattern recognition receptor (Pattern recognition receptor, PRR), thereby eliciting excessive activation of the innate immune response and degradation of mRNA.
In recent years, based on species diversity, with intensive research, more Cap structures have been found, and in addition to the most common m7GPPPN Cap structures of eukaryotes, 2,7-m3GPPPN, 5' - γ -mPPPN, mGpppN, gpppN, gpppmNm, m G (5 ') ppp (5 ') m62AMPAMPCMPM Um (Cap 4), etc., as well as Nicotinamide Adenine Dinucleotide (NAD) caps originally found in bacteria and yeast have also been identified in mammalian cells. Furthermore, commercially available co-transcribed caps for mRNA have been developed with capping analogs such as m7G (5 ') ppp (5') (2 'OMeA) pG, m7 (3' OMeG) (5 ') ppp (5') (2 'OMeA) pG, m7G (5') ppp (5 ') (2' OMe, m 6A) pG, etc., and mRNA co-transcribed cap analogs based on sense strand RNA viruses
M7G (5 ') ppp (5 ') (2 ' OMeA) pU. Because of the increasing variety of existing cap structures and the increasing demand for mass detection of mRNA capping rate, there is a need to develop a technical method for mass detection of mRNA capping rate. The current method for determining mRNA cap type and capping efficiency mainly comprises the following steps: ELISA (for example, chinese patent application CN105209633A combines an anti-m 7G specific antibody with a cap structure, and combines a first antibody with a second antibody, and quantitative detection of RNA capping efficiency is performed by ELISA, the method requires a specific reagent to be used as a standard curve, the applicable cap structure is limited, the precision easily varies from batch to batch due to different samples), HPLC chromatography (for example, chinese patent application CN105051213A requires an appropriate chromatographic column, the cap structure requires larger separation of capped and uncapped sample peaks from the chromatogram easily, the method only can quantitatively analyze samples with obvious variation of mRNA capping and uncapped sample quantities, the method can accurately analyze the capping rate of a sample by means of mass spectrometry, but has high equipment requirement, and is limited to the capping rate analysis of enzymatic capping), time-of-flight mass spectrometry (for example, the method has high equipment requirement, and the used capping and uncapped sequences are limited, only for capping rate detection of fixed sequence mRNA, the application range is limited), RT-qPCR (for example, the patent CN114395613B provides a method for detecting the capping enzyme activity of vaccinia virus in vitro by using RT-qPCR, by detecting CT value difference, thereby determining the activity of vaccinia virus capping enzyme. But this method is applicable only to enzymatic capping detection) and the like. In addition, most of the existing detection methods are manually operated, and no automatic processing and batch processing methods of mRNA samples exist, so that large differences exist in manually operated samples among batches, and the standard requirements of quality controllability of the samples among batches are difficult to realize.
Capillary electrophoresis (CAPILLARY ELECTROPHORESIS, CE) technology is a method of separating and analyzing biomolecules (nucleic acids, proteins, polypeptides, sugars, etc.) based on differences in charge and molecular weight. The charged biological molecules are moved in the charged capillary by an electric field, and molecules with different sizes, charges and shapes are separated. mRNA is a single-stranded biological macromolecule composed of nucleotides, with negatively charged properties. Since nucleic acid mRNA has a negative charge, under the action of an electric field, the differences based on mRNA size, morphology, and charge density can move and segregate differently in capillaries. The specific process of mRNA isolation involves a number of factors including pH of the buffer, ion concentration and type, type and size of capillary material, and the like. In practical applications, adjustments and optimizations are required for different samples and experimental purposes. By optimizing experimental conditions, efficient, high-resolution separation and quantification of nucleic acid samples can be achieved. In summary, capillary electrophoresis technology is widely used in biomedical, molecular biology, food science, and other fields.
Chinese patent application CN115678968a discloses a method for detecting mRNA capping efficiency using capillary electrophoresis. The patent adopts a manual operation method, is mainly used for detecting the structure of the m7GPPPN hat, and has a single detection object; the selected site of the probe is nucleotide in the 10 th-85 th region of the 5 'end of the 5' UTR, and the probe is not designed from the beginning, so that the selectable sequence interval of the probe is limited; because the probe designed from the head can be more difficult to distinguish between uncapped sequences and electrophoresis peaks of the capping sequences in capillary electrophoresis, a detection method technology with better resolution is needed, however, the peak images of the results obtained by the method are not independent but are adhered together, so that the accuracy of calculation of the detection result of the capping rate can be affected; the DNA probe designed by the patent needs to be subjected to enzymolysis twice after being combined with the mRNA to be tested, namely DNase enzymolysis is needed after RNase enzymolysis.
Therefore, developing a complete set of simple, economical, efficient, batch and high-resolution method for detecting mRNA capping efficiency through automatic processing is one of the problems to be solved urgently in mRNA drug research and drug production quality inspection.
Disclosure of Invention
The invention aims to provide a method for automatically detecting mRNA capping rate in batches by utilizing a capillary electrophoresis technology.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a method for automatically detecting mRNA capping rate in batches by utilizing capillary electrophoresis technology, which comprises the following steps:
(1) Designing a hybridization probe according to the sequence of the 5' UTR region of mRNA to be detected;
(2) Denaturing and annealing the hybridization probe and mRNA to be detected to obtain a heterozygous sequence;
(3) Directionally cutting the heterozygous sequence by using RNA hydrolase, purifying and then carrying out high-temperature denaturation and dissociation to obtain a mixture containing the probe, capped mRNA and uncapped mRNA;
(4) And (3) performing capillary electrophoresis on the mixture extracted in the step (3), and calculating the capping rate of the mRNA to be detected according to the capillary electrophoresis result.
Preferably, the hybridization probe is reverse-complementary to the mRNA to be detected.
Preferably, the hybridization probe is designed according to the base sequence of the 5'UTR region of the mRNA to be detected from the 1 st to 100 th region of the 5' end.
Preferably, the length of the hybridization probe is more than or equal to 15nt.
Preferably, the cap structure of the mRNA to be tested comprises: cap structure of the 5 'end of natural mRNA, synthetic cap structure analogs with modified or unmodified mRNA 5' end.
Preferably, the addition ratio of the mRNA to be detected and the hybridization probe in the step (2) is 1:1-1:5.
Preferably, the denaturing conditions of step (2) are: denaturation at 90-100 ℃ for 1-10 min, and annealing: annealing at 70 deg.C, and cooling to room temperature at-10 deg.C/2 min.
Preferably, the RNA hydrolase in the step (3) is one of RNase H, RNase HI and RNase II.
Preferably, the temperature of the high-temperature denaturation dissociation in the step (3) is 70-100 ℃ and the time is 2-10 minutes.
Preferably, the length of the capillary tube in the step (4) is 10-60 cm.
Preferably, the capillary electrophoresis in the step (4) further comprises a reverse electrophoresis program, wherein the reverse electrophoresis time is 10-60 minutes, and the gel preservation temperature is 2-8 ℃ during electrophoresis.
The invention designs a hybridization probe according to the 5' UTR region sequence of mRNA to be detected, then hybridizes the hybridization probe with the mRNA to be detected to obtain a heterozygous sequence, and carries out enzymolysis, purification and high-temperature denaturation and dissociation on the heterozygous sequence to obtain probe, capped and uncapped mRNA sequences. The mRNA capping rate is analyzed by an automatic nucleic acid sample processing system and capillary electrophoresis equipment with good sensitivity, high resolution and accurate precision, and the automatic batch quantitative detection of the mRNA capping rate can be realized by setting a reverse electrophoresis program and a specific gel casting and gel storage program, and once the program is set, the mRNA capping rate can be stably operated without complex operation. And the capillary gel is stored at 2-8 ℃, so that the stability of the gel property can be maintained within 24 hours, the repeated balance and gel filling of the editing program are carried out at intervals, and a stable mRNA capping rate batch detection result can be obtained.
The capillary electrophoresis spectrum obtained by the method has smooth characteristic peak base line, high signal-to-noise ratio and high separation degree between signal peaks although the molecular weights of the capped sample and the uncapped sample are similar. For a plurality of mRNA capping samples, reverse electrophoresis procedures are added through single glue filling, and electrophoresis can be performed through multiple sample injections, so that capping rate detection results of the plurality of samples are obtained, and batch detection is realized. The invention has simple operation, low consumable cost, accurate and repeatable experimental result, and is very suitable for quality verification in mRNA medicine industrialization.
Drawings
FIG. 1 is a capillary electrophoresis diagram of an enzyme-cleaved capped (G) probe of example 3;
FIG. 2 is a capillary electrophoresis of the capped (G) sample of example 3;
FIG. 3 is a capillary electrophoresis of an uncapped (G) sample of example 3;
FIG. 4 is a capillary electrophoresis of a sample mixture of capped (G) and uncapped (G) of example 3;
FIG. 5 is a capillary electrophoresis of a capped (U) sample of example 3;
FIG. 6 is a capillary electrophoresis chart of internal reference markers (20 nt, 50nt, 70nt and 100 nt) in example 3.
Detailed Description
The invention provides a method for automatically detecting mRNA capping rate in batches by utilizing capillary electrophoresis technology, which comprises the following steps:
(1) Designing a hybridization probe according to the sequence of the 5' UTR region of mRNA to be detected;
(2) Denaturing and annealing the hybridization probe and mRNA to be detected to obtain a heterozygous sequence;
(3) Directionally cutting the heterozygous sequence by using RNA hydrolase, purifying and then carrying out high-temperature denaturation and dissociation to obtain a mixture containing the probe, capped mRNA and uncapped mRNA;
(4) And (3) performing capillary electrophoresis on the mixture obtained in the step (3), and calculating the capping rate of the mRNA to be detected according to the capillary electrophoresis result.
In the present invention, the hybridization probe is reverse-complementary to the mRNA to be measured.
In the invention, the hybridization probe is designed according to the base sequence in the 1 st to 100 th regions of the 5 'end of the 5' UTR region sequence of mRNA to be detected, and the length of the hybridization probe is more than or equal to 15nt.
In the present invention, the hybridization probe is preferably further coupled with biotin for purification by coupling with streptavidin magnetic beads.
In the present invention, the cap structure of the mRNA to be measured comprises: the cap structure of the 5 'end of the natural mRNA, and the cap structure analogue of the 5' end of the artificial mRNA with modification or non-modification are preferably G, U, A, C caps and N nucleotide analogues thereof (N is more than or equal to 1).
In the invention, the addition ratio of the mRNA to be detected and the hybridization probe in the step (2) is 1:1-1:5.
In the present invention, the conditions for the denaturation in the step (2) are as follows: denaturation at 90-100℃for 1-10 min, preferably 95℃for 5min.
In the present invention, the annealing in step (2) is: annealing at 70 deg.C, and cooling to room temperature at-10 deg.C/2 min.
In the present invention, the RNA hydrolase in step (3) is one of RNase H, RNase H I and RNase H II, preferably RNase H.
In the present invention, the temperature of the RNA hydrolase cleavage reaction is 35 to 40℃for 1 to 4 hours, preferably 37℃for 3 hours.
In the present invention, the temperature of the high temperature denaturation dissociation in the step (3) is 70 to 100℃for 2 to 10 minutes, preferably 80℃for 3 minutes.
In the present invention, the processes of steps (2) and (3) are performed on an automatic nucleic acid extractor, which is: thermo Scientific KingFisherApex nucleic acid purification system or Roche MagNAPure LC fully automated nucleic acid purification and sample addition system, preferably Thermo Scientific KingFisherApex nucleic acid purification system.
In the invention, the length of the capillary tube in the step (4) is 10-60 cm.
In the present invention, the time for the capillary electrophoresis in the step (4) is 50 to 70 minutes, preferably 60 minutes.
In the present invention, the capillary electrophoresis of step (4) further comprises a step of adding reverse electrophoresis for 10 to 60 minutes, preferably 20 minutes, after completion of electrophoresis of each needle sample.
In the present invention, it is also necessary to add an internal nucleic acid standard for performing the capillary electrophoresis described in step (4).
In the present invention, the process of step (4) is performed on a capillary electrophoresis apparatus, which is: BECKMAN PA800 or SCIEX PA800plus.
In the present invention, the capillary electrophoresis in the step (4) further includes a step of enzyme-cutting probe electrophoresis, which can be used to detect whether the designed probe has self-cutting, and the accuracy of the result is affected by the self-cutting of the probe.
In the invention, the storage temperature of the gel used in the capillary electrophoresis in the step (4) is 2-8 ℃, the stability of the gel property can be maintained within 24 hours, the repeated balance and gel filling are performed at intervals of the editing program, and the stable mRNA capping rate batch detection result can be obtained.
In the invention, the detection method of the mRNA capping rate can be widely applied to quality control application of mRNA in basic biological research, clinical diagnosis, drug development and drug production.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
In this example, uncapped firefly luciferase (Firefly luciferase, fluc) mRNA and capped Fluc mRNA were used as detection targets. Uncapped and capped Fluc mRNA samples were prepared by in vitro transcription using the co-transcription method.
The preparation of in vitro transcription reactions and mRNA capping test samples must be performed in a completely DNase/RNase free environment and unless specified, all consumables, reagents, buffers, etc. involved require no nuclease.
(1) Preparation of conventional codon optimized uncapped Fluc mRNA samples by in vitro transcription
The linearized DNA plasmid containing the Fluc gene sequence was used as transcription template after enzyme removal purification, and was transcribed using a commercially available T7 in vitro transcription kit. The reaction system is shown in Table 1.
TABLE 1 uncapped mRNA in vitro transcription System
| Component (A) | 20 Mu L of reaction system (mu L) |
| DNase/RNase-Free Water | 6 |
| GTP(100mM) | 2 |
| ATP(100mM) | 2 |
| UTP1(100mM) | 2 |
| CTP1(100mM) | 2 |
| 10X Transcription Buffer | 2 |
| DNA template(2μg)1000ng/μL | 2 |
| T7RNA Polymerase Mix | 2 |
| Total volume of | 20 |
The components were added to a 200. Mu.L PCR tube without enzyme according to the above system, mixed and centrifuged, and then placed on a PCR instrument for reaction at 37℃for 2 hours. After completion of the transcription reaction, 2U of DNase I was added to each system and the reaction was continued at 37℃for 15 minutes to remove the template DNA. And detecting the integrity of the synthesized mRNA by using denaturing agarose gel electrophoresis, purifying to obtain an uncapped mRNA sample after the detection is qualified, and detecting the concentration of the mRNA by using a micro ultraviolet spectrophotometer. The uncapped Fluc mRNA sequence of the conventional codon optimized firefly luciferase is shown in SEQ ID No. 1.
(2) Preparation of conventional and replicative codon optimized capped Fluc mRNA samples by in vitro transcription
Using linearized DNA plasmids containing the Fluc gene sequence, after enzyme removal purification, as transcription templates, transcription synthesis was performed using a commercially available T7 in vitro transcription kit, the reaction system is shown with reference to Table 2, and cap analogs were prepared according to conventional and replicative templates using commercially available m7 (3 ' OMeG) (5 ') ppp (5 ') (2 ' OMeA) pG (G caps, then G-caps) or m7G (5 ') ppp (5 ') (2 ' OMeA) pU (U caps, then U-caps), respectively. The replication codon optimized uncapped Fluc mRNA sequence is shown in SEQ ID No. 2.
TABLE 2 capping mRNA in vitro transcription System
| Component (A) | 20 Mu L of reaction system (mu L) |
| Dnase/RNase-Free Water | 4.4 |
| GTP(100mM) | 2 |
| ATP(100mM) | 2 |
| UTP1(100mM) | 2 |
| CTP1(100mM) | 2 |
| G hat/U hat (100 mM) | 1.6 |
| 10X Transcription Buffer | 2 |
| DNA template(2μg)1000ng/μL | 2 |
| T7RNA Polymerase Mix | 2 |
| Total volume of | 20 |
The components were added to a 200. Mu.L PCR tube without enzyme according to the above system, mixed and centrifuged, and then placed on a PCR instrument for reaction at 37℃for 2 hours. After completion of the transcription reaction, 2U of DNase I was added to each system and the reaction was continued at 37℃for 15 minutes to remove the template DNA. And detecting the integrity of the synthesized mRNA by using denaturing agarose gel electrophoresis, purifying to obtain a capped mRNA sample after the detection is qualified, and detecting the concentration of the mRNA by using a micro ultraviolet spectrophotometer.
Example 2
An on-press sample for mRNA capping rate detection was prepared.
The mRNA used for the preparation of the sample on the capillary electrophoresis was an uncapped mRNA sample prepared in example 1 and two capped mRNA samples. Two hybridization probes were commissioned and biotin was coupled to were synthesized by Shanghai Biotechnology Inc.:
Probe G(SEQ ID NO：3)：AATACTAGUUUAUUCUCCCU/3BioTEG/
Probe U(SEQ ID NO：4)：AAAATCUUUUGGCGUCGUGU/3BioTEG/
mRNA synthesized in example 1 was denatured and annealed with each probe according to the system of Table 3. The reaction procedure for automated sample processing is shown in table 4.
TABLE 3 denaturation annealing of mRNA to probes
After the addition of the components is completed, the components are evenly mixed and centrifuged.
The mixed samples of Table 3 were transferred to 96-well deep well plates, placed on the control panel of Thermo Scientific KingFisherApex nucleic acid purification system, and automated mRNA sample processing procedures were set according to Table 4 (magnetic beads were added during processing for purification of the probe and the hybridized fragments of mRNA).
TABLE 4 automated mRNA sample processing procedure
Through the procedure, purification of the mRNA capping rate detection sample is completed, and the sample can be detected by using capillary electrophoresis after cooling to room temperature.
Example 3
This example uses a capillary electrophoresis device to detect the capping rate of mRNA. The upper sample used was the upper sample obtained by the treatment in example 2: uncapped (G) on-machine samples, capped (G) on-machine samples, on-machine samples where uncapped (G) and capped (G) are mixed by equal mass, capped (U) on-machine samples. And (5) adjusting the sample loading volume to 20 mu L by using enzyme-free water, and performing on-machine detection.
The conditions used for capillary electrophoresis are: the capillary length is 60cm, the capillary electrophoresis temperature is 30 ℃, the electrophoresis voltage is 30kV, the ultraviolet light collection wavelength is 254nm, and the sample injection time is 15 seconds. The storage temperature of the gel was 8 ℃. The program sequence is set forth in table 5.
TABLE 5 automated mRNA (G) capping Rate detection procedure
In order to detect the presence or absence of self-cleaving sites in the probe, which affects the reaction efficiency of the probe, a step of adding a separate cleavage probe and running the capillary electrophoresis is required in the first test. In this example, the results of the capillary electrophoresis of the enzyme-cleaved probe G are shown in FIG. 1 (Table 5, no. 1). As shown in FIG. 1, the capillary electrophoresis diagram of the enzyme-cleaved probe G shows that the probe is a single peak, which indicates that the probe screened by computer assistance has no self-cleavage site, has good hybridization performance in theory, and is suitable for detecting the capping rate of mRNA.
In the in vitro co-transcription capping reaction, capping mRNA and unsuccessfully capped mRNA exist in the reaction system due to the competitive relationship between the cap structure and the nucleotide G and the difference of capping efficiency. After RNase H directional enzyme cutting, magnetic beads can be utilized to specifically capture mRNA fragments complementary to a hybridization region of the probe through biotin labels on the probe, after high-temperature denaturation, the mRNA fragments (containing capped mRNA and unsuccessfully capped mRNA fragments) of the complementary region of the probe are dissociated in a solution, and differences of electrophoresis speed of each fragment can be generated through capillary electrophoresis, so that each fragment is distinguished on a capillary electrophoresis chart, and the capping rate can be calculated through the peak area ratio of capped mRNA to total mRNA (containing capped mRNA and uncapped mRNA).
The ratio of peak areas of the individual peaks was obtained by software calculations (fig. 2, table 7), and the capping rate of the mRNA capping (G) samples was 4.71/(0.93+4.71) ×100% =83.51% according to the values of table 7.
TABLE 7 peak area ratio of individual peaks for mRNA capped (G) and uncapped samples
| PK# | Name | Time | Corrected Area | Corrected Area Percent |
| 1 | Probe with a probe tip | 42.48 | 5432.78 | 94.36 |
| 2 | Uncapped peaks in samples | 44.65 | 53.73 | 0.93 |
| 3 | Capping peaks in samples | 44.92 | 271.10 | 4.71 |
FIG. 3 is an uncapped (G) sample containing only probe peaks and uncapped (G) sample peaks using capillary electrophoresis.
FIG. 4 is a capillary electrophoresis plot of a mixture of capped (G) and uncapped (G) samples, labeled with the peak exit positions of the probe, uncapped (G) and capped (G), where the peak pattern of the probe, uncapped (G) and capped (G) samples in the mixture of FIG. 4 is consistent with the peak pattern of the capped (G) sample alone of FIG. 2.
Fig. 5 is a capillary electrophoresis chart of a capped (U) sample, and the ratio of peak areas of the peaks (table 8) was obtained by software calculation, so that the capping ratio of the U cap (fig. 5) was 27.46/(7.49+27.46) ×100% =78.57%.
TABLE 8 mRNA peak area ratio of individual peaks for capped (U), uncapped samples
| PK# | Name | Time | Corrected Area | Corrected Area Percent |
| 1 | Probe with a probe tip | 41.88 | 3311.46 | 65.05 |
| 2 | Uncapped peaks in samples | 44.55 | 381.27 | 7.49 |
| 3 | Capping peaks in samples | 44.70 | 1398.15 | 27.46 |
In addition, the steady state of instruments, accessories and procedures can be monitored by adding internal reference markers (20 nt, 50nt, 70nt and 100 nt) (fig. 6), while the molecular weight of the sample can be accurately analyzed using the internal standard and the functions of the software itself. Thus, the invention is a method that is well suited for batch detection of mRNA capping rates.
In the embodiment 3, the characteristic peak baseline of each map is smooth, the signal to noise ratio is high, the molecular weight of a capped sample is similar to that of an uncapped sample, but the separation degree between the two signal peaks is high, so that the invention can design a synthetic probe according to the sequence of mRNA to be detected, protect mRNA from degradation of RNA hydrolase through hybridization of the mRNA to be detected and the probe, and obtain the sequence of the mRNA 5' end containing the cap structure region after purification and high-temperature denaturation. The mRNA capping rate is analyzed by an automatic nucleic acid sample processing system and capillary electrophoresis equipment with good sensitivity, high resolution and accurate precision, and the automatic batch quantitative detection of the mRNA capping rate can be realized by setting a reverse electrophoresis program and a specific gel casting and gel storage program, and once the program is set, the mRNA capping rate can be stably operated without complex operation. The method disclosed by the invention is simple to operate, low in consumable cost, accurate and repeatable in experimental result, and very suitable for quality verification in the industrialization of mRNA medicaments.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310642481.5A CN116640833B (en) | 2023-06-01 | 2023-06-01 | A method for automatically batch detecting mRNA capping rate using capillary electrophoresis technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310642481.5A CN116640833B (en) | 2023-06-01 | 2023-06-01 | A method for automatically batch detecting mRNA capping rate using capillary electrophoresis technology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116640833A CN116640833A (en) | 2023-08-25 |
| CN116640833B true CN116640833B (en) | 2024-11-26 |
Family
ID=87639659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310642481.5A Active CN116640833B (en) | 2023-06-01 | 2023-06-01 | A method for automatically batch detecting mRNA capping rate using capillary electrophoresis technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116640833B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116875658B (en) * | 2023-09-09 | 2024-02-06 | 南京鸿明生物科技有限公司 | Deoxyribozyme and method for detecting mRNA capping rate |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115678968A (en) * | 2021-07-22 | 2023-02-03 | 仁景(苏州)生物科技有限公司 | Method for detecting mRNA capping efficiency |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014152673A1 (en) * | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Quantitative assessment for cap efficiency of messenger rna |
| CN115346595A (en) * | 2021-05-12 | 2022-11-15 | 上海细胞治疗集团有限公司 | Method for measuring mRNA average molecular weight and Cap0/1, modified nucleotide and oxide |
| CN114894916A (en) * | 2022-04-02 | 2022-08-12 | 翌圣生物科技(上海)股份有限公司 | Method for detecting RNA capping efficiency |
-
2023
- 2023-06-01 CN CN202310642481.5A patent/CN116640833B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115678968A (en) * | 2021-07-22 | 2023-02-03 | 仁景(苏州)生物科技有限公司 | Method for detecting mRNA capping efficiency |
Non-Patent Citations (3)
| Title |
|---|
| Label-free analysis of mRNA capping efficiency using RNase H probes and LC-MS;Michael Beverly等;《Anal Bioanal Chem》;20160518 * |
| RNase H-based analysis of synthetic mRNA 5’cap incorporation;S. HONG CHAN等;《RNA》;20220609;第28卷(第8期);第1144-1155页 * |
| The yeast scavenger decapping enzyme Dcps and its application for in vitro RNA recapping;Madalee G. Wulf等;《Scientific Reports》;20190613;第9卷 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116640833A (en) | 2023-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116626142B (en) | A method for detecting the length of mRNA Poly(A) tail | |
| CN116640833B (en) | A method for automatically batch detecting mRNA capping rate using capillary electrophoresis technology | |
| CN117467742A (en) | Method for detecting polyA tail length of mRNA | |
| CN116426610B (en) | Method for accurately quantifying mRNA capping efficiency by LC-MS method | |
| CN116735729A (en) | mRNA and capping enzyme activity detection kit, detection system, detection method and application | |
| CN114395613B (en) | Method for detecting activity of capping enzyme of vaccinia virus | |
| CN114250268A (en) | Product for detecting capping efficiency of mRNA sample and application | |
| KR101913735B1 (en) | Internal control substance searching for intersample crosscontamination of nextgeneration sequencing samples | |
| CN113265452A (en) | Bioinformatics pathogen detection method based on Nanopore metagenome RNA-seq | |
| CN116103373A (en) | Kit for enriching and amplifying urine eccDNA, method and application | |
| CN116949156A (en) | Analysis method for detecting human T cells in general way based on nucleic acid variants | |
| CN116497019A (en) | Transcription buffer solution capable of improving in-vitro synthesized RNA yield and transcription reaction system | |
| WO2023115495A1 (en) | Method for measuring mrna capping efficiency using mass spectrometry | |
| CN102154504B (en) | HRM joint detection method of ADSL and LPL genes related to chicken quality and flavor | |
| CN112501321B (en) | Method for molecular typing of mycobacterium tuberculosis | |
| CN116064853A (en) | Kit and application thereof | |
| CN116287109A (en) | A method for measuring single-molecule RNA force spectrum and its application | |
| CN114507720A (en) | Mycobacterium tuberculosis drug resistance gene locus, primer set and detection method based on MassARRAY nucleic acid mass spectrometry platform | |
| CN113817849A (en) | Primer group for detecting mycobacteria based on nucleic acid mass spectrometry technology and application thereof | |
| CN111154836A (en) | Targeted nucleic acid capture and detection methods | |
| CN111172254A (en) | Detection method and kit for SMN1 gene mutation | |
| CN114934100B (en) | Kit for detecting residual DNA of Vero cells by using real-time fluorescence RAA method and detection method thereof | |
| CN117487934B (en) | Primer probe combination, kit and detection method for detecting MDCK cell tumorigenicity related genes | |
| CN120005972A (en) | Method for analyzing capping rate of mRNA (messenger ribonucleic acid) by using label-free RNase H (ribonucleic acid) probe and LC-MS (liquid crystal-mass spectrometry) | |
| CN118222669A (en) | Method for detecting plasmid PolyA (T) fragment length distribution by using capillary electrophoresis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |